Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
Aaron T. Gerds, Claire Harrison, Jean‐Jacques Kiladjian, et al.
Blood Advances (2024) Vol. 8, Iss. 17, pp. 4511-4522
Open Access | Times Cited: 15

Showing 15 citing articles:

Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Blood (2024) Vol. 144, Iss. 17, pp. 1813-1820
Closed Access | Times Cited: 9
Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1‐Positive and ‐Negative Myeloproliferative Neoplasms
Tariq I. Mughal, John O. Mascarenhas, Raajit K. Rampal, et al.
Hematological Oncology (2025) Vol. 43, Iss. 1
Closed Access
Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms
Ayalew Tefferi, Naseema Gangat
American Journal of Hematology (2025)
Closed Access
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2025)
Closed Access
Momelotinib Usage Within Our Current Canadian Myelofibrosis Armamentarium
Sonia Cerquozzi
Canadian Hematology Today (2025)
Closed Access
Momelotinib for the treatment of myelofibrosis
Prithviraj Bose
Blood (2024) Vol. 144, Iss. 7, pp. 708-713
Closed Access | Times Cited: 1
Identifying disease-modifying potential in myelofibrosis clinical trials
David M. Ross, Steven Lane, Claire Harrison
Blood (2024) Vol. 144, Iss. 16, pp. 1679-1688
Closed Access | Times Cited: 1
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what’s the current standard of care?
Mahesh Swaminathan, Akhil Jain, Sungchul Daniel Choi, et al.
Expert Review of Hematology (2024)
Closed Access | Times Cited: 1
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib
Haifa Kathrin Al‐Ali, Andrew Kuykendall, Catherine Ellis, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4064-4064
Open Access | Times Cited: 1
SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis
Michael J. Hochman, Colin A. Vale, Anthony M. Hunter
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Anemia response in myelofibrosis revisited
Ashish Bajel
Blood (2024) Vol. 144, Iss. 17, pp. 1759-1760
Closed Access
What are the therapeutic options for previously treated myelofibrosis?
C. Petit, Hugues de Lavallade, Claire Harrison
Expert Review of Hematology (2024), pp. 1-12
Closed Access
Investigational drugs in early phase trials for myelofibrosis
Sankalp Arora, Pankit Vachhani, Prithviraj Bose
Expert Opinion on Investigational Drugs (2024), pp. 1-14
Closed Access
Novel approaches in myelofibrosis
Steffen Koschmieder
HemaSphere (2024) Vol. 8, Iss. 12
Open Access
Treatment of Philadelphia Chromosome-negative Myeloproliferative Neoplasms in 2024: A Concise Review
Akhil Rajendra, Dawn Maze
Canadian Hematology Today (2024)
Closed Access
Page 1

Scroll to top